What if we could combine our autofluorescent viruses with state of the art nebulization chambers to investigate airborne disinfection? What if we had the ability to measure and visualize if a room has been correctly decontaminated ? What if we could measure viral persistence following airborne dispersion. Well, we can. We are very proud to announce our strategical alliance with VirexpR, the leader in airborne disinfection testing in France. This collaboration will allow NeoVirTech to use VirexpR nebulization room (2,5 and 20m³) to disperse its autofluorescent virus and to measure the efficiency of air treatment devices using an imaged based readout. The alliance provides customer with a unique way to measure and visualize directly airborne disinfection efficiency and efficacy of respiratory protection for example. Contact us to know more : contact@neovirtech.com, contact@virexpr.fr

NeoVirTech (NVT) and BioImmunitas Ltd enter a long-term partnership to advance a human recombinant protein therapeutic platform from bench to bedside. BioImmunitas Ltd has developed a highly cost-efficient series of recombinant proteins which form the platform therapeutic agent. This highly innovative treatment has been shown to be efficacious in several different therapeutic areas. Their collaboration with NeoVirTech has seen BioImmunitas utilize NVT’s proprietary antiviral discovery platform to position its own therapeutic hRPP on the anti-viral market.

NeoVirTech SAS opens a new laboratory at the Toulouse Cancer Research Center (CRCT) to structure its anti-cancer programs towards the creation of a patient-oriented theranostics platform, and to promote drug development

VirHealth SAS and NeoVirTech SAS announce the creation of a strategical alliance to create one of the most advanced private virus disinfection platform in Europe.